Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease (HOPE Kids 2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04218084|
Recruitment Status : Active, not recruiting
First Posted : January 6, 2020
Last Update Posted : February 24, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease||Drug: Voxelotor Drug: Placebos||Phase 3|
Expanded Access : An investigational treatment associated with this study is temporarily not available outside the clinical trial. More info ...
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||236 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Masking Description:||Double-Blind, Placebo-Controlled|
|Official Title:||A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease|
|Actual Study Start Date :||April 7, 2021|
|Estimated Primary Completion Date :||March 2025|
|Estimated Study Completion Date :||March 2025|
Voxelotor 1500mg or equivalent daily as a tablet, dispersible tablet, or as powder for oral suspension.
Participants are randomized 1:1 to receive voxelotor or placebo.
Placebo Comparator: Placebo
- TCD Measurement [ Time Frame: 24 weeks ]The change in time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow, as measured by TCD.
- Change in TCD Flow Velocity [ Time Frame: 48 and 96 weeks ]
- Conversion to Abnormal TCD Flow Velocity [ Time Frame: 24, 48, and 96 weeks ]Incidence of conversion to abnormal TCD flow velocity (≥ 200 cm/sec)
- Reversion to Normal TCD Flow Velocity [ Time Frame: 24, 48, and 96 weeks ]Incidence of reversion to normal TCD flow velocity (<170 cm/sec)
- TCD Flow Velocity Reduction [ Time Frame: 24, 48, and 96 weeks ]Proportion of participants with TCD flow velocity reduction ≥ 15 cm/sec
- Number of Participants with Change in Hemoglobin (Hb) [ Time Frame: 24, 48, and 96 weeks ]
- Change in Unconjugated Bilirubin [ Time Frame: 24, 48 and 96 weeks ]
- Change in Percent of Reticulocyte [ Time Frame: 24, 48, and 96 weeks ]
- Change in Absolute Reticulocyte [ Time Frame: 24, 48, and 96 weeks ]
- Change in Lactate Dehydrogenase (LDH) [ Time Frame: 24, 48, and 96 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||2 Years to 14 Years (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female participants with Sickle Cell Anemia (SCA)
- TCD time averaged maximum of the mean velocity (TAMMV) arterial cerebral blood flow ≥ 170 to < 200cm/sec during the Screening Period
- Hb ≥ 5.5 and ≤ 10.5 g/dL during screening
- For participants taking HU, the dose of HU (mg/kg) must be stable for at least 90 days prior to signing the informed consent form (ICF) and/or assent form, and with no anticipated need for dose adjustments (other than weight based) or for initiation of HU for non-chronic use during the study, in the opinion of the Investigator
- Written informed parental/guardian consent and participant assent (where applicable) has been obtained per IRB/EC policy and requirements, consistent with ICH guidelines.
- Body weight < 10kg at the screening visit
- Hospitalization for VOC or acute chest syndrome (ACS) within the 14 days prior to execution of informed consent/assent (see Section 184.108.40.206 for the definition of VOC).
- More than 10 VOCs within the past 12 months that required hospitalization, emergency room, or clinic visit
- Stroke resulting in focal neurological deficit; previous silent infarcts are permitted.
- Known history or findings suggestive of significant cerebral vasculopathy (eg, moyamoya or significant vasculopathy)
- History of seizure disorder
- Has been treated with erythropoietin or other hematopoietic growth factors within 28 days of signing informed consent/assent or if, in the opinion of the Investigator, there is an anticipated need for such agents during the study
- RBC transfusion therapy (also termed chronic, prophylactic, or preventative transfusion) or has received an RBC transfusion or exchange transfusion for any reason within 90 days of signing the informed consent/assent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04218084
|Responsible Party:||Global Blood Therapeutics|
|Other Study ID Numbers:||
|First Posted:||January 6, 2020 Key Record Dates|
|Last Update Posted:||February 24, 2023|
|Last Verified:||August 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Sickle Cell Disease
Transcranial Doppler Ultrasound (TCD)
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn